

JUN. 25. 2004 2:04PM AVENTIS US PAT DEPT
TO: US USPTO GENERAL

RECEIVED
CENTRAL FAX CENTER

NO. 4613 P. 1

JUN 25 2004

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
DEAV2001-0004 US NP

Applicants:
STROBEL et al.

Serial No.
10/073,160

Filing Date:
February 13, 2002

Title of Invention:
Acyalted Indanyl Amines and Their Use as Pharmaceuticals

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at **703-872-9306**, on
Date of Deposit **June 25, 2004**

Printed Name of Person Signing Certificate **Paul Irvine**

Signature 

Total Number of Pages Sent: 6

Attorney: **George Wang**

Group Art Unit: **1626**

Examiner: **Kamal A Saeed**

TO:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|------------------------------------------------------------------------------|------------------------------------------------------|
| <input checked="" type="checkbox"/> Amendment, 37 CFR <u>1.111</u> - 4 pages | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition - 1 page | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com

NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

JUN 25 2004

PATENT**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of
STROBEL et al.

Examiner: Kamal A Saeed

Application No.: 10/073,160

Art Unit: 1626

Filed: February 13, 2002

TELEFAX CERTIFICATE

Title: **Acylated Indanyl Amines and Their Use
as Pharmaceuticals**I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-
1450, at 703-872-9306, onJune 25, 2004
Date of Transmission

Signature

OFFICIAL**RESPONSE TO OFFICE ACTION**Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The following remarks are submitted in response to the Office Action mailed February 25, 2004. Applicants respectfully submit that the Examiner's objection of claims 1-6, 21 and 22 as containing non-elected subject matter is improper and should be withdrawn.

REMARKS

The Examiner divided the present application into three groups (Group I, II and III) and requested applicants to elect one group for further examination. Pursuant to this request, applicant elected Group I (claims 1-6, 21 and 22), drawn to compounds of Formula I defined in claim 1. The Examiner further stated that "claim 1 is generic to a plurality of disclosed patentably distinct species" and thus required Applicants to provisionally elect a single species for initial examination of Group I. Following applicant's election of a single species (2,2-difluoro-benzo[1,3]dioxol-5-carboxylic acid indan-2-ylamide), the Examiner arbitrarily picked a number of species from the claims as selected subject matter and treated the remaining species as non-selected subject matter. It was on that basis that the pending claims were objected to for containing non-selected subject matter.